The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with a MDM2 inhibitor for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and a MDM2 inhibitor.La présente invention concerne la thérapie dassociation dun anticorps afucosylé anti-CD20 avec un inhibiteur MDM2 pour le traitement du cancer, en particulier la thérapie dassociation de cancers exprimant CD20 avec un anticorps afucosylé humanisé B-Ly1 et un inhibiteur MDM2.